A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost
BACKGROUND: The development of an effective HIV-1 vaccine is critical to control the pandemic. A prime-boost HIV-1 vaccine trial assessing safety and immunogenicity was conducted in Thailand as part of an evaluation of candidate regimens for a phase 3 efficacy trial. METHODS: ALVAC-HIV (vCP1521), ex...
محفوظ في:
المؤلفون الرئيسيون: | Prasert Thongcharoen, Vinai Suriyanon, Robert M. Paris, Chirasak Khamboonruang, Mark S. De Souza, Silvia Ratto-Kim, Chitraporn Karnasuta, Victoria R. Polonis, Lynn Baglyos, Raphaelle El Habib, Sanjay Gurunathan, Susan Barnett, Arthur E. Brown, Deborah L. Birx, John G. McNeil, Jerome H. Kim |
---|---|
التنسيق: | دورية |
منشور في: |
2018
|
الموضوعات: | |
الوصول للمادة أونلاين: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=34848908400&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/61274 |
الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
المؤسسة: | Chiang Mai University |
مواد مشابهة
-
A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost
بواسطة: Prasert Thongcharoen, وآخرون
منشور في: (2018) -
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand
بواسطة: Punnee Pitisuttithum, وآخرون
منشور في: (2018) -
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: A post-hoc analysis of the Thai phase 3 efficacy trial RV 144
بواسطة: Merlin L. Robb, وآخرون
منشور في: (2018) -
HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting
بواسطة: Paris R., وآخرون
منشور في: (2014) -
HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting
بواسطة: R. Paris, وآخرون
منشور في: (2018)